ScholarLens Back to search
2007•Clinical MedicineRequires access

Comparative study on clinical effects of lamivudine and entecavir in treatment of chronic hepatitis gravis

Ying Guihu

Open publisher page 0 citations

Abstract

Objective To evaluate the short-term of lamivudine and entecavir in treatment of chronic hepatitis gravis.Methods Seventy-two patients with chronic hepatitis gravis were divided into lamivudine group and entecavir group.One group received lamivudine for 24 weeks,the other received entecavir for 24 weeks,and patients in both groups received conventional treatment.Results After 24 weeks of treatment,the negativity of HBV DNA in entecavir group was significantly higher than that in lamivudine group.ALT and TBIL decrease levels in entecavir group was significantly higher than that in lamivudine group.Conclusion The short-term efficacy of entecavir treatment for chronic hepatitis gravis is better than lamivudine treatment.

About this research paper

What this paper is about

Objective To evaluate the short-term of lamivudine and entecavir in treatment of chronic hepatitis gravis.Methods Seventy-two patients with chronic hepatitis gravis were divided into lamivudine group and entecavir group.One group received lamivudine for 24 weeks,the other received entecavir for 24 weeks,and patients in both groups received conventional treatment.Results After 24 weeks of treatment,the negativity of HBV DNA in entecavir group was significantly higher than that in lamivudine group.ALT and TBIL decrease levels in entecavir group was significantly higher than that in lamivudine group.Conclusion The short-term efficacy of entecavir treatment for chronic hepatitis gravis is better than lamivudine treatment.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the short-term of lamivudine and entecavir in treatment of chronic hepatitis gravis.Methods Seventy-two patients with chronic hepatitis gravis were divided into lamivudine group and entecavir group.One group received lamivudine for 24 weeks,the other received entecavir for 24 weeks,and patients in both groups received conventional treatment.Results After 24 weeks of treatment,the negativity of HBV DNA in entecavir group was significantly higher than that in lamivudine group.ALT and TBIL decrease levels in entecavir group was significantly higher than that in lamivudine group.Conclusion The short-term efficacy of entecavir treatment for chronic hepatitis gravis is better than lamivudine treatment.

Key concepts: Lamivudine, Entecavir, Medicine, Chronic hepatitis, Internal medicine, Gastroenterology, Hepatitis a virus, Virology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Comparative study on clinical effects of lamivudine and entecavir in treatment of chronic hepatitis gravis — Research Paper | ScholarLens